keyword
MENU ▼
Read by QxMD icon Read
search

Melanoma AND surgery

keyword
https://www.readbyqxmd.com/read/29453679/the-impact-of-timing-of-immunotherapy-with-cranial-irradiation-in-melanoma-patients-with-brain-metastases-intracranial-progression-survival-and-toxicity
#1
Rifaquat Rahman, Alfonso Cortes, Andrzej Niemierko, Kevin S Oh, Keith T Flaherty, Donald P Lawrence, Ryan J Sullivan, Helen A Shih
Immunotherapy (IT) is increasingly incorporated in the management of metastatic melanoma patients with brain metastases, but the impact of timing of IT with stereotactic radiosurgery (SRS) remains unclear. The aim of this study was to determine the temporal significance of IT in melanoma patients treated with cranial radiation therapy (RT) with respect to patterns of intracranial progression, overall survival (OS), and toxicity. We retrospectively reviewed consecutive melanoma patients with brain metastases undergoing cranial RT and IT between 2008 and 2015...
February 16, 2018: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/29453209/recurrent-epistaxis-leading-to-diagnosis-of-primary-sinonasal-melanoma
#2
Karine Tawagi, Rita Akaraz-Avedissian, Irina Burman-Solovyeva
A 48-year-old man presented to urgent care with recurrent epistaxis over 6 months. Initially, nosebleeds were controlled with packing or cautery. Ultimately, he was referred to ear, nose and throat department and underwent nasal endoscopy which revealed polypoid tissue. A biopsy of the polyp showed non-specific inflammation with no evidence of malignancy. Follow-up maxillofacial CT revealed a large mass lesion in the right maxillary sinus, right nasal fossa, much of the ethmoids and right sphenoid, with destruction of adjacent bony structures...
February 16, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/29449898/targeted-therapy-of-brain-metastases-latest-evidence-and-clinical-implications
#3
REVIEW
Rodica Di Lorenzo, Manmeet S Ahluwalia
Brain metastases (BM) occur in 20-40% of patients with cancer and 60-75% of patients with BM become symptomatic. Due to an aging population and advances in the treatment of primary cancers, patients are living longer and are more likely to experience complications from BM. The diagnosis of BM drastically worsens long-term survival rates, with multiple metastases being a poor prognostic factor. Until recently, the mainstay of treatment consisted of stereotactic radiosurgery (SRS), surgical resection, whole brain radiation therapy (WBRT), or a combination of these modalities...
December 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/29449519/-supratentorial-meningeal-melanoma-with-nevus-of-ota-a-case-report
#4
Shogo Shima, Shinsuke Sato, Yosuke Moteki, Tatsuya Inoue, Kosuke Suzuki, Yasunari Niimi, Yoshikazu Okada
We present a rare case of supratentorial meningeal melanoma associated with ipsilateral nevus of Ota, and a review of the literature. The patient was a 32-year-old man with a right-sided nevus of Ota, presenting with unconsciousness. His CT and MRI scans revealed an extra axial tumor with dural tail signs; no lesion was detected on systemic examination. Intraoperatively, the tumor demonstrated black hyperpigmentation and was histologically diagnosed as malignant melanoma. Following surgery, he received radiotherapy and chemotherapy...
February 2018: No Shinkei Geka. Neurological Surgery
https://www.readbyqxmd.com/read/29441722/the-growing-importance-of-lesion-volume-as-a-prognostic-factor-in-patients-with-multiple-brain-metastases-treated-with-stereotactic-radiosurgery
#5
David M Routman, Shelly X Bian, Kevin Diao, Jonathan L Liu, Cheng Yu, Jason Ye, Gabriel Zada, Eric L Chang
Stereotactic Radiosurgery (SRS) is considered standard of care for patients with 1-3 brain metastases (BM). Recent observational studies have shown equivalent OS in patients with 5+ BM compared to those with 2-4, suggesting SRS alone may be appropriate in these patients. We aim to review outcomes of patients treated with SRS with 2-4 versus 5+ BM. This analysis included consecutive patients from 1994 to 2015 treated with SRS. Of 1017 patients, we excluded patients with a single BM and patients without adequate survival data, resulting in 391 patients...
February 14, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29441097/the-feasibility-of-using-ultrasound-during-follow-up-for-superficial-non-melanoma-skin-cancers-after-electronic-brachytherapy
#6
Uma Goyal, Justin Suszko, Baldassarre Stea
Purpose: Non-melanoma skin cancers (NMSCs) can be treated with a number of modalities including surgery, topical chemotherapy, or radiotherapy. Amongst the radiotherapeutic options, electronic brachytherapy (eBT) is an appealing treatment as it is usually given in a few fractions, it leads to good outcomes, and is increasingly being used. However, currently no follow-up imaging is routinely used or recommended to evaluate treatment response of NMSC. We aimed to use ultrasound (US) in follow-up after eBT for superficial NMSC to assess its feasibility in detecting possible tumor response...
December 2017: Journal of Contemporary Brachytherapy
https://www.readbyqxmd.com/read/29433557/metastatic-uveal-melanoma-showing-durable-response-to-anti-ctla-4-and-anti-pd-1-combination-therapy-after-experiencing-progression-on-anti-pd-1-therapy-alone
#7
Muhammad Zubair Afzal, Rodwell Mabaera, Keisuke Shirai
BACKGROUND: Uveal melanoma accounts for 85% of the ocular melanomas and has an increased risk of hematogenous spread, most commonly to the liver. After curative intent therapy like surgery and radiation, fifty percent of patients present with distant metastasis. Metastatic uveal melanoma (MUM) does not harbor typically targetable mutations, e.g., BRAF as in cutaneous melanoma. As a result, there is no proven therapy for MUM. Various chemotherapy and immunotherapy regimens have been tried and only partial response (PR) is the best that has been achieved in most of the cases...
February 12, 2018: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/29430695/immunocryosurgery-as-monotherapy-for-lentigo-maligna-or-combined-with-surgical-excision-for-lentigo-maligna-melanoma
#8
Clara Matas-Nadal, Xavier Sòria, María R García-de-la-Fuente, Valentín Huerva, Eugenia Ortega, Felip Vilardell, Sònia Gatius, Josep M Casanova, Rosa M Martí
The incidence of lentigo maligna (LM), in situ (LM) or invasive (lentigo maligna melanoma, LMM), has increased during the last decades. Due to functional or cosmetic outcomes, optimal treatment with surgical excision may not be appropriate in some cases. We tried less invasive therapy, immunocryosurgery, as a single treatment for LM or combined with surgery for LMM, with better aesthetic results. Three patients with LM or LMM not amenable to complete surgical excision were selected. LMM patients underwent limited surgical resection of the invasive area...
February 11, 2018: Journal of Dermatology
https://www.readbyqxmd.com/read/29419913/variation-in-the-diagnosis-and-clinical-management-of-lentigo-maligna-across-europe-a-survey-study-among-eadv-members
#9
D Tio, C A C Prinsen, B Dréno, R Hoekzema, M Augustin, C van Montfrans
BACKGROUND: Lentigo maligna (LM), a form of melanoma in situ, is treated to prevent progression to lentigo maligna melanoma (LMM). Surgical treatment is the gold standard. However, treatment guidelines are based on expert opinion and comparative studies are lacking. OBJECTIVE: The objective of this study is to assess the diagnostic methods and clinical management of LM patients among European dermatologists and residents. METHODS: A survey consisting of 29 questions about diagnostic methods and treatment options used for LM patients was sent to 3308 members of the European association of Dermatologists and Venereologists (EADV)...
February 8, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29409139/withdrawn-chemoimmunotherapy-versus-chemotherapy-for-metastatic-malignant-melanoma
#10
REVIEW
Andre D Sasse, Emma C Sasse, Luciana Go Clark, Otavio Augusto Camara Clark
BACKGROUND: Malignant melanoma, one of the most aggressive of all skin cancers, is increasing in incidence throughout the world. Surgery remains the cornerstone of curative treatment in earlier stages. Metastatic disease is incurable in most affected people, because melanoma does not respond to most systemic treatments. A number of novel approaches are under evaluation and have shown promising results, but they are usually associated with increased toxicity and cost. The combination of chemotherapy and immunotherapy has been reported to improve treatment results, but it is still unclear whether evidence exists to support this choice, compared with chemotherapy alone...
February 6, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29394786/-anorectal-malignant-melanoma-is-a-very-rare-disease-and-has-a-poor-prognosis
#11
Yuta Yoshida, Shingo Noura, Tae Matsumura, Masaki Hirota, Takashi Shuto, Arisa Muratsu, Harunobu Yasuyama, Akihiro Takata, Chikato Koga, Chizu Kameda, Masahiro Murakami, Ryohei Kawabata, Junzo Shimizu, Hideaki Miwa, Junichi Hasegawa
We performed abdomino-perineal-resection(APR)on 2 cases of anorectal malignant melanoma. The first case was a 70- year-old woman suffering from bloody stool. Colonoscopy showed a black tumor in the rectum. Biopsy revealed a malignant melanoma. A CT scan showed multiple lung metastases and liver metastasis. She underwent surgery for the purpose of bleeding control, but died shortly thereafter because her liver and lung metastases had worsened. The second case was a 43- years-old man suffering from bloody stool...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29394463/primary-orbital-melanoma-treated-with-orbital-exenteration-and-postoperative-radiotherapy-a-case-report-and-review-of-the-literature
#12
Christopher P Haskins, Sommer Nurkic, Kristianna M Fredenburg, Peter T Dziegielewski, William M Mendenhall
BACKGROUND: We report on a patient with human immunodeficiency virus (HIV)-positive disease with a primary orbital melanoma treated with surgery and adjuvant radiation. METHODS: A 53-year-old woman with HIV-positive disease presented with left-sided progressive ipsilateral vision loss and proptosis. An MRI scan revealed a mass-enhancing lesion measuring 2.1 × 2.6 × 2.5 cm abutting the optic nerve. The patient underwent left orbital exenteration with temporalis flap reconstruction, pathology revealing malignant melanoma, stage T1N0M0...
February 2, 2018: Head & Neck
https://www.readbyqxmd.com/read/29394206/secondary-glaucoma-due-to-iridescent-crystalline-particles-masquerading-as-refractory-hypertensive-uveitis-in-an-eye-with-irradiated-iris-melanoma
#13
Rupinder Chahal, Abhijit Anand Mohite, Heinrich Heimann, Atul Bansal
PURPOSE: We report a previously unrecognised mechanism of secondary glaucoma due to iridescent crystalline particles released from an irradiated iris melanoma. It masqueraded as refractory hypertensive uveitis following uncomplicated phacoemulsification. METHODS: A 58-year-old gentleman had an iris melanoma that underwent successful regression following irradiation with proton beam radiotherapy (PBRT). Three years later an uncomplicated phacoemulsification with intraocular lens implant was performed and subsequently the patient presented with apparently "refractory hypertensive uveitis"...
February 1, 2018: Journal of Glaucoma
https://www.readbyqxmd.com/read/29393881/the-role-of-photodynamic-therapy-in-the-treatment-of-vulvar-intraepithelial-neoplasia
#14
REVIEW
Giulio Tosti, Anna Daniela Iacobone, Eleonora Petra Preti, Sabina Vaccari, Alessia Barisani, Elisabetta Pennacchioli, Carmen Cantisani
BACKGROUND: vulvar intraepithelial neoplasia is a non-invasive precursor lesion found in 50-70% of patients affected by vulvar squamous cell carcinoma. In the past, radical surgery was the standard treatment for vulvar intraepithelial neoplasia, however, considering the psychological and physical morbidities related to extensive surgery, several less aggressive treatment modalities have been proposed since the late 1970s. Photodynamic therapy is an effective and safe treatment for cutaneous non-melanoma skin cancer, with favorable cosmetic outcomes...
February 2, 2018: Biomedicines
https://www.readbyqxmd.com/read/29392067/defect-reconstruction-of-the-nose-after-surgery-for-nonmelanoma-skin-cancer-our-clinical-experience
#15
İsa Kaya, Mustafa Uslu, Fazıl Apaydın
Objective: This study aimed to investigate reconstruction methods according to nasal subunits in patients who were surgically treated with diagnosis of non-melanoma skin cancer of the nose. Methods: All patients were retrospectively investigated. This study was conducted between April 2004 and December 2010; 180 patients who were surgically treated with diagnoses of skin basal cell carcinoma, squamous cell carcinoma, cancer of skin appendages, and precancerous lesions and 194 lesions were included...
September 2017: Turkish Archives of Otorhinolaryngology
https://www.readbyqxmd.com/read/29390427/primary-adrenal-malignant-melanoma-a-case-report-and-review-of-literature
#16
Bo Xu, Yazhao Hong, Meishan Jin, Mingyang Li, Chunxi Wang, Xiaoqing Wang
RATIONALE: The primary adrenal melanoma (PAM) was an extremely rare occurrence, which was demonstrated as the few cases described in the medical literature. PATIENT CONCERNS: We reported a 58-year-old man who was admitted to hospital because of intermittent left flank pain which lasted for a month. The renal computed tomography (CT) scan showed that a large retroperitoneal tumor measuring 15.5 cm × 12.1 cm × 13.0 cm seemed to have its origin in the left adrenal gland...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29389234/duration-of-anti-programmed-death-1-therapy-in-advanced-melanoma-how-much-of-a-good-thing-is-enough
#17
Nikhil I Khushalani
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice...
February 1, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29388353/clinical-patterns-and-management-of-primary-mucosal-melanoma-a-single-centre-experience
#18
Yvonne Y R Ng, Grace H C Tan, Richard H H Quek, Mohamad B H R Farid, Khee Chee Soo, Melissa C C Teo
BACKGROUND: Primary mucosal melanomas (MM) are rare neoplasms arising from melanocytes in mucosal membranes. Delayed diagnosis and aggressive disease biology contribute to a poorer prognosis. The clinical patterns of MMs treated in a large tertiary centre, and the differences between MMs in the head and neck versus other anatomical sites are described. METHODS: A retrospective review of 43 patients diagnosed with MM in the head and neck, urogenital, esophageal and anorectal sites from 1993 to 2015 was conducted...
February 1, 2018: ANZ Journal of Surgery
https://www.readbyqxmd.com/read/29382618/primary-meningeal-melanocytoma-in-sellar-region-simulating-a-nonfunctioning-pituitary-adenoma-a-case-report-and-literature-review
#19
Fei Wang, Shiying Ling
BACKGROUND: and Importance Primary meningeal melanocytoma (PMM) is a benign lesion in the central nervous system derived from leptomeningeal melanocytes, most commonly growing in the posterior fossa and cervical spinal cord. The primary sellar melanocytoma is an exceptionally rare tumor. The authors reported the ninth published case of a sellar primary meningeal melanocytoma (SPMM). CLINICAL PRESENTATION: The patient presented only with visual impairment and irregular menstruation without other symptoms...
January 27, 2018: World Neurosurgery
https://www.readbyqxmd.com/read/29361468/neoadjuvant-plus-adjuvant-dabrafenib-and-trametinib-versus-standard-of-care-in-patients-with-high-risk-surgically-resectable-melanoma-a-single-centre-open-label-randomised-phase-2-trial
#20
Rodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, Alexandre Reuben, Miles C Andrews, Merrick I Ross, Isabella C Glitza, Janice Cormier, Wen-Jen Hwu, Hussein A Tawbi, Sapna P Patel, Jeffrey E Lee, Jeffrey E Gershenwald, Christine N Spencer, Vancheswaran Gopalakrishnan, Roland Bassett, Lauren Simpson, Rosalind Mouton, Courtney W Hudgens, Li Zhao, Haifeng Zhu, Zachary A Cooper, Khalida Wani, Alexander Lazar, Patrick Hwu, Adi Diab, Michael K Wong, Jennifer L McQuade, Richard Royal, Anthony Lucci, Elizabeth M Burton, Sangeetha Reddy, Padmanee Sharma, James Allison, Phillip A Futreal, Scott E Woodman, Michael A Davies, Jennifer A Wargo
BACKGROUND: Dual BRAF and MEK inhibition produces a response in a large number of patients with stage IV BRAF-mutant melanoma. The existing standard of care for patients with clinical stage III melanoma is upfront surgery and consideration for adjuvant therapy, which is insufficient to cure most patients. Neoadjuvant targeted therapy with BRAF and MEK inhibitors (such as dabrafenib and trametinib) might provide clinical benefit in this high-risk p opulation. METHODS: We undertook this single-centre, open-label, randomised phase 2 trial at the University of Texas MD Anderson Cancer Center (Houston, TX, USA)...
January 17, 2018: Lancet Oncology
keyword
keyword
58182
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"